ENTRECTINIB-STARTRK

NCT02568267 📎

Regimen

Experimental
Entrectinib (pan-TRK/ROS1/ALK inhibitor)
Control
single-arm basket (no control)

Population

NTRK fusion-positive solid tumors (tissue-agnostic), any line, TRK inhibitor naive; CRC subgroup reported separately.

Key finding

Efficacy-evaluable n=54 (10 different tumor types, 19 histologies): ORR 57% (95% CI 43.2–70.8), 4 CR + 27 PR; median duration of response 10 months (7.1–NE); grade 3–4 AEs: weight increase 10%, anaemia 12%; no treatment-related deaths; CNS efficacy demonstrated (unique vs larotrectinib).

Source: PMID 31838007

Timeline

    Guideline citations

    • NCCN Colon (p.50)
    • NCCN Rectal (p.67)